Cervical I/F Cage for Anterior Cervical Fusion
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the clinical success of the Cervical I/F Cage in treatment of one or two adjacent levels of degenerative disc disease of the cervical spine compared with standard of care treatment using either autograft, autograft with a plate or allograft with a plate
| Condition | Intervention | Phase |
|---|---|---|
|
Degenerative Disc Disease in One or Two Adjacent Levels in the Cervical Spine |
Device: Cervical I/F Cage Procedure: Standard Cervical Fusion |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Randomized Multi-Center Study to Evaluate the Safety and Efficacy of the Cervical I/F Cage for Anterior Cervical Fusion |
- Fusion Status
- Neck Disability Index
- Neurological Status
- Secondary Surgical Interventions
- Adverse Events
- Donor Site Pain
- Neck Pain
- Arm Pain
- Disc Space Height
- Sagittal Alignment
- SF-36, Health Related Quality of Life
| Estimated Enrollment: | 240 |
| Study Start Date: | August 2000 |
This is a prospective randomized multi-center clinical trial to assess the safety and efficacy of the investigational device, Cervical I/F Cage for fusion in one or two adjacent levels of the cervical spine. Patients will be randomly assigned in a ration of 1:1 between the investigational and control groups.
Comparison: The device will be compared to a control group consisting of the 3 accepted standard of care treatments (autograft, autograft with an anterior plate, or allograft with an anterior plate). For two level fusions, the control group will be limited to autograft with a plate or allograft with a plate. Based on the current literature, it is believed that there is no difference between the three treatments in terms of clinical success, fusion success, or safety issues. However, amongst the investigators there are preferred treatments. Each investigator will choose one or more of the control treatments at study initiation. Patients will then be randomized in a 1:1 Cage:control randomization schema. Approximately 240 subjects will be enrolled at 20 sites. Eligible patients will have symptomatic degeneration of one or two adjacent cervical discs, have failed six weeks of non-surgical treatment, have sufficiently severe enough symptoms to warrant surgery, and have had no prior fusion surgery on the cervical spine.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Persistent recurrent neck and/or shoulder and arm pain refractory to 6 weeks of non-surgical therapy.
- Radiographic evidence of significant disc degeneration at one or two adjacent cervical levels (C4-7)
Exclusion Criteria:
- Significant degeneration at more than two cervical levels,
- Prior surgical treatment of the cervical spine; laminotomy or foraminotomy allowed,
- Gross instability due to trauma,
- Disability in the lumbar spine,
- Infection in the disc or spine, past or present,
- Any active infection at time of surgery,
- Tumor in the spine,
- Significant osteoporosis or metabolic bone disease,
- Pregnant, lactating or wishes to become pregnant within duration of the study,
- Refusal to accept the use of autograft tissue.
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00215293 History of Changes |
| Other Study ID Numbers: | G000019 |
| Study First Received: | September 13, 2005 |
| Last Updated: | October 3, 2006 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by DePuy Spine:
|
fusion cervical spine |
Additional relevant MeSH terms:
|
Intervertebral Disk Degeneration Spinal Diseases Bone Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on May 16, 2013